MOTs-cMitochondrial signaling for metabolism, energy, and composition.
A 16-amino-acid peptide encoded in mitochondrial DNA, studied for obesity and osteoporosis.
MOTs-c is the mitochondrial peptide people want when metabolism and energy feel stuck. An FDA advisory committee recommended it for compounding in July 2026. Join the waitlist for first access when pharmacy-sourced MOTs-c can be evaluated through AlphaMD.
By joining, you opt in to launch and marketing email about MOTs-c from AlphaMD. You can unsubscribe at any time.
- U.S. compounding pharmacies only
- Discreet shipping
- 100% confidential
Why MOTs-c Gets Attention
A peptide written inside your mitochondria — not your nucleus.
Almost every peptide in medicine is encoded by nuclear DNA. MOTs-c is not. Its 16 amino acids sit in a short open reading frame within the mitochondrial 12S ribosomal RNA gene — DNA inherited only from your mother. Its identification in 2015 helped show that mitochondria send signals out to the rest of the cell, not just supply energy.
The proposed mechanism centers on AMPK, the enzyme cells use when energy runs low. Skeletal muscle appears to be a primary target. Under metabolic stress, MOTs-c has been observed moving into the nucleus and shifting antioxidant and stress-response gene expression. In mice, administered MOTs-c blunted diet-induced obesity and age-related insulin resistance. In animal models it also encouraged bone formation and slowed bone loss.
Human data so far measures the MOTs-c your body already makes: muscle levels rise sharply after exercise, circulating levels decline with age, and lower levels show up more often in type 2 diabetes. Those correlations are scientifically interesting — they are not the same as proof that injecting MOTs-c produces weight loss. A Phase 2a trial is now recruiting. In July 2026 an advisory committee recommended compounding inclusion 7–5 with two abstentions.
Where MOTs-c Stands Today
- Recommended for compoundingAdvisory vote 7–5 (2 abstentions), July 23, 2026
- FDA scientists advised against itAgency staff recommended no; the advisory committee voted yes 7–5
- No human dosing trials yetFDA found no study administering MOTs-c to people, and no in-vivo pharmacokinetics
- Banned in tested sportNamed by WADA as a metabolic modulator and prohibited at all times
- Previously flagged by the FDAPlaced in the "significant safety risks" compounding category in September 2023
- Prescription-only at launchProvider evaluation and intake required — no direct purchase
Observational human data on your own MOTs-c levels is not the same as dosing-trial proof. Final compounding still needs FDA rulemaking — the waitlist is first access when that path opens.
What You May Get From MOTs-c
The metabolic upsides people want — with a clear split between measuring the peptide you make and administering more of it.
Metabolic regulation
Administered MOTs-c blunted diet-induced obesity and improved glucose handling in mice. Obesity was one of the two uses the FDA reviewed. This is not a GLP-1, and human weight-loss trials have not been published yet.
Animal dataHuman observational data
Muscle MOTs-c climbs after exercise, falls with age, and runs lower in type 2 diabetes. Useful biology about the peptide your body makes — not proof that injecting it drives those outcomes.
Human observationalBone formation and bone loss
Promoted osteogenesis in rat marrow stromal cells and reduced bone loss after ovariectomy. Osteoporosis was the second use the FDA reviewed on this preclinical package.
Animal dataExercise adaptation
Sometimes called an "exercise mimetic" because it touches AMPK pathways training also activates — a research hypothesis, not a substitute for training.
Animal dataVascular calcification
Reduced arterial calcification in a rat model. Early and mechanistically interesting — still far from a measured human outcome.
Animal dataWho MOTs-c May Be A Fit For
A provider makes this call with you after reviewing your history and labs.
- Working on metabolic health with real numbers behind it — fasting insulin, A1c, and lipids, not a scale reading alone.
- Already training and eating well, and treating peptides as an addition rather than a shortcut.
- Following the mitochondrial research and ready for a provider-led plan while human dosing trials catch up.
- Watching age-related bone loss — alongside a DEXA scan and treatments that already have fracture outcome data.
- Already an AlphaMD member whose metabolic labs are being tracked over time anyway.
Who Should Skip It
Practical fit filters — a provider will decline when these apply.
- You need a proven weight-loss medication. MOTs-c is not an approved obesity drug. Approved options carry human outcome data that administered MOTs-c does not have yet.
- You compete in a tested sport. WADA names MOTs-c as a metabolic modulator and prohibits it at all times.
- You take insulin or a sulfonylurea. A peptide studied for glucose handling has never been tested alongside those drugs. Hypoglycemia risk needs a careful workup.
- You have untreated fatigue or unexplained weight change. Thyroid disease, anemia, sleep apnea, and depression present this way — get the workup first.
- You're pregnant, nursing, or trying to conceive. No reproductive or developmental safety data exists.
What To Know About Risks
MOTs-c has no established human side-effect profile from dosing trials. Here is what the research and nearest analog actually show.
No human dosing data and no pharmacokinetics yet
FDA identified no study administering MOTs-c to a person, and no in-vivo pharmacokinetic work. Where an injected dose goes and how long it lasts are still open questions.
It may break down quickly in blood
In human whole blood, MOTs-c is rapidly clipped into shorter fragments. Whether an injected dose reaches a useful active concentration is still unknown.
What the closest analog showed
CB4211, a MOTs-c analog, ran a Phase 1a/1b trial in 88 participants. It met its safety endpoint; injection-site reactions were common, and it did not reduce liver fat better than placebo.
Unmapped metabolic interactions
Insulin, metformin, sulfonylureas, GLP-1 medications, fasting, and hard training all move blood glucose. Interactions with MOTs-c have not been characterized in people.
Self-reported effects with no denominator
USADA has noted self-experimenters reporting elevated heart rate, palpitations, and injection-site reactions. Uncontrolled reports cannot establish cause — they are still the only human accounts available.
Gray-market product quality
For a peptide without human pharmacokinetics, vial contents are the largest controllable risk. Pharmacy testing is the reason to wait.
Pharmacy-Sourced Beats Gray-Market Guesswork
MOTs-c sells briskly online as a metabolism and longevity product, nearly always "for research use only." Independent testing of gray-market peptide vials keeps finding the same failures.
Gray-market vials
- Peptide content well under — or over — what the label claims
- Bacterial endotoxin from non-sterile production — a fever and sepsis risk you inject directly
- Residual synthesis solvents, heavy metals, and truncated peptide fragments
- Certificates of analysis that are copied, expired, or for an entirely different lot
- No prescriber, no recall path, and no one accountable if you're harmed
A U.S. compounding pharmacy
- State-licensed, FDA-inspected facility working from a real prescription
- Sterile compounding standards for anything injected, with documented process controls
- Third-party potency, sterility, and endotoxin testing tied to your specific lot
- A provider who sets your dose, reviews your labs, and owns follow-up
- Traceability — if a lot is bad, it can be found, pulled, and reported
When MOTs-c launches with AlphaMD, members get pharmacy-sourced product after a provider evaluation — not a research vial from a stranger.
Educational Resources
Deeper reading on where MOTs-c comes from, what human measurements show, and why sourcing decides most of the risk.
MOTs-c benefits, risks, and side effects: what you need to know
The long-form deep dive: mitochondrial-DNA origin, AMPK story, endogenous vs administered data, and what the FDA concluded.
The FDA reviewed seven popular peptides. Here is what each one may do.
BPC-157, KPV, TB-500, MOTs-c, DSIP, Semax, and Epitalon side by side — reviewed uses, vote counts, and how far the evidence goes.
Are your peptides even real? Why 1 in 5 tested vials came back mislabeled
What third-party assays keep finding inside gray-market vials — wrong potency, wrong sequence, and mismatched certificates.
Frequently Asked Questions
Still deciding? Message the team — you don't need to be a member to ask.
Ask a QuestionFirst access when pharmacy-compounded MOTs-c can be offered through AlphaMD — provider evaluation, intake, and product from a U.S. compounding pharmacy with lot-level testing.
In July 2026 an FDA advisory committee recommended MOTs-c for the 503A bulk-substances list. Final rulemaking still has to finish. Once a pharmacy AlphaMD trusts can lawfully produce and test it, the waitlist gets the email that week.
Not yet. Nothing on this page is for sale. If a clinic is offering MOTs-c today, ask which licensed U.S. pharmacy compounded it and for lot-specific testing.
No. It is not FDA-approved for weight loss, and there is no published human trial showing administered MOTs-c produces meaningful weight loss. Mice on a high-fat diet gained less weight when given it — a real animal finding, not a GLP-1 substitute.
Not by itself. Your body releases peptides in specific tissues, at specific concentrations, on a schedule. An injection bypasses those controls. Insulin is endogenous too — dosing still needs medical oversight.
Yes. A Phase 2a trial (NCT07505745) is comparing MOTs-c with placebo for insulin sensitivity in people with prediabetes and overweight or obesity. It is recruiting and has not published results yet.
No. Exercise changes fitness, strength, bone, mood, sleep, and insulin sensitivity together. Touching one energy-sensing pathway does not reproduce that. Training stays the base; peptides are an add-on if appropriate.
Skip it. WADA names MOTs-c as a metabolic modulator, prohibited at all times. It will not be prescribed to a tested athlete through AlphaMD.
Pricing is not set until a supplier is locked. When it is, it will be published the same way TRT pricing is: one clear number, per month.
Explore Other Peptides
Five more on the same July 2026 compounding slate — join each waitlist for first access when they launch.
Get First Access to MOTs-c
Join the waitlist for pharmacy-sourced MOTs-c through AlphaMD — provider evaluation, tested product, discreet shipping. Already a member? Bring peptides up at your next visit or book a consult to get intake done early.
By joining, you opt in to launch and marketing email about MOTs-c from AlphaMD. You can unsubscribe at any time.
No insurance needed · Cancel anytime · 100% confidential
Legal Disclaimer
MOTs-c is not an FDA-approved drug and is not currently available for sale or prescription through AlphaMD. Nothing on this page is an offer to sell, and nothing here is medical advice. Statements about potential benefits describe published preclinical research and human observational studies of naturally occurring MOTs-c and are not claims about outcomes for any individual. Peptide therapy, if and when offered, will require a consultation with a licensed medical professional, a completed medical intake, and appropriate laboratory testing; it is not appropriate for everyone. MOTs-c is named on the World Anti-Doping Agency Prohibited List as a metabolic modulator and is prohibited at all times.
Medical services are provided by independent, licensed providers through AlphaMD's affiliated professional practices. AlphaMD provides administrative and technology services and does not practice medicine.